Skip to search formSkip to main contentSkip to account menu

OC000459

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Ocular allergy: update on clinical trials.
PURPOSE OF REVIEW The purpose of this article is to provide an update on the advances made through recent clinical trials… 
Review
2017
Review
2017
Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway.
Review
2017
Review
2017
Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives
Prostaglandin D2 (PGD2) released by degranulating mast cells is believed to play a key role in orchestrating mechanisms of… 
Review
2016
Review
2016
Investigational prostaglandin D2 receptor antagonists for airway inflammation
ABSTRACT Introduction: By activating DP1 and DP2 receptors on immune and non-immune cells, prostaglandin D2 (PGD2), a major… 
2014
2014
The Potent and Selective CRTH2 Antagonist OC000459 Is Effective In The Treatment Of Eosinophilic Asthma When Given Once Daily
2013
2013
Releasing the brake on puberty.
What is so magical about the age at onset of puberty in humans — currently set at approximately 11 years of age?1 Why not 6 or 16… 
Highly Cited
2012
Highly Cited
2012
Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459
CRTH2 (chemoattractant receptor expressed on T-helper (Th) type 2 cells) is a G-protein-coupled receptor expressed by Th2… 
Highly Cited
2012
Highly Cited
2012
Pharmacologic Profile of OC000459, a Potent, Selective, and Orally Active D Prostanoid Receptor 2 Antagonist That Inhibits Mast Cell-Dependent Activation of T Helper 2 Lymphocytes and Eosinophils
D prostanoid receptor 2 (DP2) [also known as chemoattractant receptor-homologous molecule expressed on T helper 2 (Th2) cells… 
2012
2012
856 Treatment of Eosinophilic Esophagitis With the CRTH2-Antagonist Oc000459: A Novel Therapeutic Principle
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)